03:25 PM EDT, 07/24/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target to $316 from $276, 17.9x our 2027 EPS forecast, a premium to historical due to a higher expected growth outlook. We lift our 2025 EPS view to $16.33 from $16.06 and keep 2026 at $17.64. LH reported Q2 EPS of $4.35 vs. $3.94, a $0.19 consensus beat. The Diagnostics Laboratories segment, which contributes the majority of revenue, posted strong results with sales increasing to $2.75B (+8.9% Y/Y). Organic growth of 4.5% was supported by requisition volume growth (+3.4%) and price/mix improvement (+1.1%). Further, Biopharma Laboratory Services continued its momentum with revenue growing to +11.0% Y/Y due to strong performance by early Development services. LH continues to grow inorganically, with several bolt-on acquisitions in progress including select assets from Incyte Diagnostics. Management raised its 2025 EPS guidance by $0.23 at the midpoint to a new $16.05-$16.50 range. We expect strong performance to continue into 2H 2025 given high health care utilization trends industry-wide.